Bo Liang

Dr. Liang currently serves as Director of the company, responsible for overseeing all project development and the company’s strategy and operations. In 2015, Dr. Liang co-founded iVIEW Therapeutics, Inc. and acquired global rights of Deda Pharmaceuticals’ all IP assets, and also filed new IP applications based on new discoveries.

Dr. Bo Liang is a serial entrepreneur with over 15 years of experience in drug discovery research, chemical and material sciences, biotechnology and materials venture, and management. In 2006, Dr. Liang co-founded CLS Pharmaceuticals in New York City, where he invented a combination drug of Povidone Iodine and Dexamethasone, for the treatment of viral conjunctivitis. Within two years he has advanced the drug candidate into phase II trial, resulting in an out-license to Foresight Biotherapeutics in 2008. From 2008-2010, Dr. Liang served as Executive Vice President, Pharmaceutical Development at Foresight to head the CMC development of the drug program for FST-100. After accomplishing phase II trials, the program was acquired by Shire Pharmaceuticals for $300m in 2015.

Dr. Liang was once a medicinal chemist at Pharmacopeia, Inc., where he made a key contribution to the alpha 2C program and led a new drug discovery program in treating respiratory diseases. Dr. Liang has published over 15 scientific articles and is the inventor on over 40 issued patents and patent applications. He was once Journal “Bioorganic and Medicinal Chemistry” invited reviewer. Besides his interest in topical drug development and innovative drug delivery technology, he was also CEO of Adesso Advanced Materials, which he co-founded in 2010 focusing on developing the world's first recyclable resin materials in the carbon fiber composite industry. Now Adesso has an R&D operations and manufacturing base in Wuxi and Wuhu, China, and an EU business development center in Cambridge, UK. Adesso’s recyclable resin was first commercialized in carbon fiber composite sporting goods applications such as fishing rods and bicycles with target applications in the lightweight automotive industry.

Dr. Liang obtained his BSc. in chemistry from Peking University in China in 1992, then was educated in the US and got his Ph.D. in synthetic organic chemistry from the University of Pennsylvania in 2001. He also obtained his MBA concentrating in entrepreneurship, and Finance from NYU Stern School of Business in 2008.